Impact of Functioning Metastatic Neuroendocrine Tumors
|
|
- Leonard Edwards
- 5 years ago
- Views:
Transcription
1 Clinical Overview and Treatment Advances in Carcinoid Syndrome Sponsored by Lexicon Pharmaceuticals Impact of Functioning Metastatic Neuroendocrine Tumors Evaluation & Management 1
2 Presentation objectives By the end of this presentation, attendees will have learned about: Epidemiology and clinical characteristics of neuroendocrine tumors The role of serotonin in carcinoid syndrome The complications of carcinoid syndrome Carcinoid syndrome diarrhea management 3 Introduction to Neuroendocrine Tumors (NETs) 2
3 NETs: Not Your Typical Tumors Family of malignancies originating from neuroendocrine cells throughout the body 1 Often misunderstood and often present at an advanced stage 1 Increasingly common 1 Can be aggressive, treatment resistant, and potentially life threatening 1,2 Induce debilitating hormonal syndromes NET=neuroendocrine tumor. 5 Carcinoid Syndrome Is an Ultra-Orphan Disease ~13,000 Patients Are Currently Living With Carcinoid Syndrome in the United States NETs 1 ~103,000 patients GEP-NETs ~61% 2 ~62,500 patients Non-GEP-NETs ~39% 3 ~40,000 patients Patients with functioning carcinoid tumors 10%-20% 4,5,a ~13,000 Patients Nonfunctioning carcinoid tumors ~80% ~50,000 patients Bronchopulmonary ~69% 3 ~27,000 patients a Calculation based on 20%. 1. Yao JC, et al. J Clin Oncol. 2008;26(18): Lawrence B, et al. Endocrinol Metab Clin North Am. 2011;40(1): Frilling A, et al. Endocr Relat Cancer. 2012;19(5): R163-R National Cancer Institute. Gastrointestinal carcinoid tumors treatment for health professionals (PDQ ). Accessed February 7, Horton KM, et al. AJR Am J Roentgenol ;182(3):
4 Pathophysiology and Complications Arising from Serotonin in Carcinoid Syndrome Diarrhea Serotonin is overproduced intracellularly by functioning NETs Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in serotonin production 29 mnet cell Systemic circulation/blood stream Secretion 31 TPH is robustly expressed in functioning NETs and the resulting serotonin overproduction triggers carcinoid syndrome 14,32 Somatostatin and its receptors (SSTR2 and SSTR5) serve to block the secretion of serotonin, though NET cells may reduce SSTR concentration on the cell surface 31,32 Serotonin is converted from tryptophan by TPH and subsequently secreted by NETs into systemic circulation, where it is converted to 5-HIAA 15 mnet=metastatic NET; NETs=neuroendocrine tumors. 8 4
5 Excess serotonin has short- and long-term consequences known as Carcinoid Syndrome Overall health 36 Among patients with metastatic or advanced neuroendocrine tumors (NETs), those with carcinoid syndrome have a poorer prognosis than those with NETs alone. Short-term effects 5,15,33 Life-altering diarrhea Urgent bowel movements Flushing in the skin Long-term effects 15,33,35 Tissue fibrosis Heart (carcinoid heart disease) Lung/pulmonary Mesentery Carcinoid Syndrome 9 Carcinoid syndrome diarrhea is often debilitating and sometimes life-threatening Diarrhea occurs in >70% patients with carcinoid syndrome and may occur several times daily 5,36 Fluid loss from severe diarrhea may result in dehydration and serious health consequences 38 : 9% develop severe, life-threatening diarrhea 39 Patients can experience significant weight loss and hypoproteinemia 38 BM=bowel movement. 10 5
6 Approaches to Management for NETs and Carcinoid Syndrome Diarrhea SSAs have been the standard of care in the management of NETs and Carcinoid Syndrome diarrhea Systemic circulation/blood stream SSAs inhibit the downstream release of serotonin but do not directly inhibit serotonin production SSAs bind primarily to SSTRs 2 and 5 on the cell surface 40 They block the extracellular secretion of serotonin and other hormones 41,42 SSAs are recommended for the treatment of symptomatic and asymptomatic NETs 44 SSAs are commonly used for tumor and symptom management in patients with NETs 44 mnet=metastatic NET; NET=neuroendocrine tumor; SSA=somatostatin analog; SSTR=somatostatin receptor; TPH=tryptophan hydroxylase. SSA 12 6
7 Despite a variety of treatment options, therapies that target a root cause of carcinoid syndrome are necessary Modification of SSA dose such as shortening the treatment interval or increasing the dose are often employed however: 51 - Many patient develop tachyphylaxis potentially due to decreased receptor concentration 32 - Escalation is typically at doses that are not FDA approved 51 - There is a lack of prospective well-designed clinical evidence to support this strategy Self-administered short-acting SSA injections may also be utilized to try to reduce diarrhea, although this approach generally requires multiple daily injections 51 Patients often use non-specific treatments to halt gastric motility yet continue to remain syndromic 13 Summary NETs are a diverse family of potentially malignant neoplasms with a steadily rising incidence rate 5,2 Carcinoid syndrome is induced by the secretion of serotonin from functional NETs and is often misdiagnosed 15,16 Potentially devastating short- and long-term effects of carcinoid syndrome include life-altering diarrhea and carcinoid heart disease, respectively 5 Carcinoid syndrome treatment is imperative regardless of tumor status, as patients have long life spans and exhibit significant disease burden 36 Despite non-specific options historically, patients require additional management of their carcinoid syndrome diarrhea 52,53 NET=neuroendocrine tumor. 14 7
8 Thank you First in class: tryptophan hydroxylase inhibitor 1,2 Introducing XERMELO The first and only oral treatment for carcinoid syndrome diarrhea 1,2 8
9 XERMELO (telotristat ethyl) A tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Please see Important Safety Information throughout this presentation. Introducing Rebecca C., 62* Diagnosed with GI NET Diagnosed with carcinoid syndrome Syndrome Intensified Underwent surgery Sandostatin 30 mg/4 wk *Representative of a typical patient in the TELESTAR TRIAL. This is not an actual patient. GI=gastrointestinal; NET=neuroendocrine tumor; wk=week. 18 9
10 Rebecca s chief complaints and current therapy Chief complaints: Diarrhea Patient experiences urgent bowel movements that occasionally occur throughout the night Frequent bathroom trips lead to disruptions in the workplace and at social events Upon further probing, patient reveals that the frequency of her bowel movements has increased to 6 daily Physical exam findings: Frequent injections from SSA administration produced scar tissue in both buttocks Baseline laboratory values: u5-hiaa Levels: 91mg/24hrs Current therapy: Octreotide 30 mg/4 weeks Short-acting SSA therapy PRN Imodium/Lomotil PRN PRN=as needed; SSA=somatostatin analogue; u5-hiaa=urinary 5-hydroxyindoleacetic acid. 19 Considerations for next steps Chief complaint of diarrhea (frequency and impact to patient lifestyle) Mode of SSA administration Patient currently at maximum FDA-approved dose for Sandostatin LAR Elevated levels of u-5hiaa Upon further dialogue, the patient was started on XERMELO for the treatment of carcinoid syndrome diarrhea SSA=somatostatin analog; LAR=long-acting release; u5-hiaa=urinary 5-hydroxyindoleacetic acid
11 TELESTAR A 12-week, double-blind, placebo-controlled, randomized, multicenter, Phase III pivotal trial TELESTAR: Study design 1 XERMELO is approved based on the results of TELESTAR, a 12-week, double-blind, placebo-controlled, randomized, multicenter Phase III trial 1 Primary endpoint: Change in number of daily bowel movements. Patients were allowed to use rescue medication (short-acting octreotide) and antidiarrheals for symptomatic relief The TELESTAR study included a 36-week open-label extension investigating a higher than recommended dose of XERMELO 1 TELESTAR=Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome; mnet=metastatic neuroendocrine tumor; SSA=somatostatin analog. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February
12 TELESTAR: Baseline characteristics 1 SD=standard deviation; BM=bowel movement; u5-hiaa=urinary 5-hydroxyindoleacetic acid; SSA=somatostatin analog; H=hour. Reference: 1. Kulke MH, Hörsch D,Caplin ME, et al. J Clin Oncol. Published Online: October 28, 2016 (doi: /jco ). 23 XERMELO (telotristat ethyl) Mechanism of action 12
13 XERMELO: The first and only oral TPH inhibitor to decrease the production of serotonin, an important driver of carcinoid syndrome diarrhea 1,2 XERMELO + SSA decreases both the production of serotonin within the metastatic neuroendocrine (mnet) cell and the release of serotonin outside the cell 1-3 OUTSIDE THE mnet CELL INSIDE THE mnet CELL TPH INHIBITION AND DECREASED INTRACELLULAR SEROTONIN PRODUCTION RESULT IN 1 u5-hiaa IS A BIOMARKER IN CARCINOID SYNDROME AND IS INDICATIVE OF SEROTONIN LEVELS 5,6 References: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21: Sandostatin LAR Depot Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July Appetecchia M, Baldelli R. J Exp Clin Cancer Res. 2010;29: van der Horst-Schrivers ANA, Post WJ, Kema IP, et al. Eur J Cancer. 2007;43: Bartholomew TK, Garcia Hernandez J, Rossi RE, et al. Urinary 5-hydroxyindoleacetic acid in serotonin-producing neuroendocrine tumors: correlation with disease eatures and survival. Poster presented at: European Neuroendocrine Tumor Society 11th Annual Conference; March 5-7, 2014; Barcelona, Spain. 25 TELESTAR: 24-hour u5-hiaa levels decreased with XERMELO but not with SSA alone 1 u5-hiaa did not decrease with SSA alone 1 Reductions observed following 6 and 12 weeks of treatment 1 u5-hiaa=urinary 5-hydroxyindoleacetic acid; SSA=somatostatin analog. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February
14 XERMELO provided significant and superior reductions in mean daily bowel movements vs SSA alone (P<0.001) 1 Over 12 weeks, XERMELO + SSA delivered superior reductions in bowel-movement frequency vs SSA alone (P<0.001) 1 XERMELO + SSA provided early and sustained reductions in bowel-movement frequency, observed as early as 1 to 3 weeks and maintained throughout the 12-week study 1 SSA=somatostatin analog. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February % of patients receiving XERMELO + SSA experienced improvement in bowel-movement frequency 1 Reductions in daily bowel-movement frequency with XERMELO + SSA vs SSA alone XERMELO + SSA reduced overall average bowel-movement frequency by 2 per day in 8x more patients than SSA Alone: 33% vs 4%, respectively 1 SSA=somatostatin analog. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February
15 XERMELO + SSA reduced the use of short-acting rescue injection beyond SSA alone PATIENTS RECEIVING SSA ALONE REQUIRED MORE THAN TWICE AS MANY AVERAGE DAILY RESCUE INJECTIONS AS DID PATIENTS RECEIVING XERMELO + SSA: 0.7 VS 0.3 AVERAGE DAILY INJECTIONS, RESPECTIVELY 1 If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO SSA=somatostatin analog. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February XERMELO: Safety profile 1 *Incidence of 5% in the XERMELO treatment group and at an incidence greater than placebo. Reference: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February
16 XERMELO + Standard of Care Is Estimated to Have Minimal Budget Impact Inadequately Controlled Patient Population (Current SOC) SSA Outcomes Increase dose of LAR Increase SSA rescue use Increased incidence of CS diarrhea HCRU Budgetary Impact Year 1: $18.9M $20.4M PPPM $9.4K $10.1K PMPM $0.16 $0.17 Net PMPM $0.01 (Future SOC) SSA + TE Increase cost with Xermelo Decrease SSA rescue use Decrease incidence of CS diarrhea HCRU Population Time horizon: 3 years up to 5 years Health plan population:10m members with carcinoid syndrome (0.0042%): N=420 Members without adequately controlled carcinoid syndrome (39.92%): N=168 Data on file. SOC, Standard of Care HCRU, Health Care Related Utilization 31 XERMELO Delivers Value VALUE ~90% of payers surveyed incorporate both benefit and cost into their value assessments 1 Benefit Reduces carcinoid syndrome diarrhea symptoms Oral route of administration Cost Minimal budget impact ($0.01 PMPM) XERMELO Value XERMELO an FDA-approved combination therapy with SSA for patients with metastatic NETs and carcinoid syndrome diarrhea who are inadequately controlled by their current SSA therapy is an efficacious therapy that may fill the void left by costly, off-label dose escalation a Compared with costs associated with inadequately controlled carcinoid syndrome diarrhea (eg, ambulatory care, ER visits, inpatient stays, pharmacy cost) Abedi S. Defining value: the payer perspective. Published January 5, Accessed May 2, XERMELO [prescribing information]. The Woodlands, TX; Lexicon Pharmaceuticals, Inc.; February Data on file
17 Important Safety Information Warnings and Precautions: XERMELO may cause constipation, which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops. Adverse Reactions: The most common adverse reactions ( 5%) include nausea, headache, increased gamma-glutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure. For more information about XERMELO, please see the full Prescribing Information. 33 Rebecca at week 12 on TELESTAR BM frequency Achieved a week 12 reduction similar to the study population u5-hiaa A reduction in u-5hiaa levels was achieved at week 12 Current therapy: XERMELO 250 mg Octreotide 30 mg/4 weeks Imodium/Lomotil PRN Treatment-emergent side effects: Grade 1 headache Grade 2 nausea AS SYMPTOMS IMPROVE, IT IS CRUCIAL TO MAINTAIN A CONTINUING DIALOGUE WITH PATIENTS SURROUNDING THE FREQUENCY AND IMPACT OF DAILY BOWEL MOVEMENTS u5-hiaa=urinary 5-hydroxyindoleacetic acid; BM=bowel movement; PRN=as needed
18 XERMELO: Dosing and Adherence It is important for your patients to take XERMELO every day 1 : XERMELO works by reducing serotonin, thereby reducing carcinoid syndrome diarrhea XERMELO bioavailability is increased with food; therefore, it should be administered as 250 mg tablets 3 times daily with meals If a dose is missed, patients should be advised not to take extra doses in an attempt to compensate Reference: XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February XERMELO: The first and only oral treatment for carcinoid syndrome diarrhea 1,2 Through inhibition of tryptophan hydroxylase, XERMELO decreases the production of serotonin and the frequency of carcinoid syndrome diarrhea 1,2 89% of patients receiving XERMELO + SSA experienced improvement in bowel-movement frequency vs 69% of patients receiving SSA alone 1 XERMELO provided superior and significant reductions in daily bowel movements averaged over 12 weeks ( 1.4 with XERMELO 250 mg vs 0.6 with SSA alone; P<0.001) 1 XERMELO + SSA provided early and sustained reductions in bowel-movement frequency, observed as early as 1 to 3 weeks and maintained throughout the 12-week study 1 The most common adverse reactions ( 5%) include nausea, headache, increased gamma-glutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia 1 u5-hiaa=urinary 5-hydroxyindoleacetic acid; SSA=somatostatin analog. References: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21:
19 XERMELO: The first and only oral treatment for carcinoid syndrome diarrhea 1,2 THANK YOU For more information call 1(844) XERMELO or visit References: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21: How to Ask A Question Type your question in the Questions area 19
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationDiscovering Breakthrough Treatments for Human Disease. Discovering Breakthrough Treatments for Human Disease
Patient Reported Outcomes in Oncology Trials Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Discovering Breakthrough Treatments for Human Disease Discovering Breakthrough Treatments
More informationClinical Development in the Treatment of Carcinoid Syndrome. Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer
Clinical Development in the Treatment of Carcinoid Syndrome Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Carcinoid Syndrome Heart Pulmonic and tricuspid valve thickening Stenosis
More informationPRESS RELEASE. Beaumont et al. Pancreas Journal 2012 ; 41(3) : / 5
PRESS RELEASE Ipsen receives approval from European Commission for Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue
More informationTelotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP
Telotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationManaging Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)
Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide) INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of
More informationAUSTRALIAN PRODUCT INFORMATION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationSomatuline Depot. Somatuline Depot (lanreotide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.27 Subject: Somatuline Depot Page: 1 of 5 Last Review Date: December 8, 2017 Somatuline Depot Description
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationSOMATULINE DEPOT (lanreotide acetate)
SOMATULINE DEPOT (lanreotide acetate) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationManaging Acromegaly: Review of Two Cases
Managing Acromegaly: Review of Two Cases INDICATION AND USAGE SIGNIFOR LAR (pasireotide) for injectable suspension is a somatostatin analog indicated for the treatment of patients with acromegaly who have
More informationDiagnosing and monitoring NET
Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationSelf-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses Tara Whyand BSc MSc Neuroendocrine Tumour Research &
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sandostatin, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03.01.10 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationJaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More information3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Somatostatin Analogs (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationStrategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova
Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine
More informationPRESS RELEASE. Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
PRESS RELEASE Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors First-in-class Therapy Demonstrated 79% Improvement
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationTreatment Patterns and Outcomes in Metastatic Neuroendocrine Tumors: Results From a Retrospective Community Oncology Database
Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium Basking
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1091-7 Program Prior Authorization/Notification Medication Sandostatin (octreotide acetate) Note: Only the subcutaneous formulation
More informationGrade 2 Ileum NET with liver and bone metastasis
Grade 2 Ileum NET with liver and bone metastasis BERNARDO MARQUES ENDOCRINOLOGY DEPARTMENT PORTUGUESE INSTITUTE OF ONCOLOGY - COIMBRA April 2018, Lugano, Switzerland JPB, male, 67 years old April 2015
More informationCommunity Case. Saeed Awan R5
Community Case Saeed Awan R5 18 year old presents to ER with history of pain right lower quadrant for three days. Nauseated, denies vomiting and bowel movements normal and no urinary complaint. Admitted
More informationPATIENT GUIDE. Highlights of Important Safety Information Warnings and Precautions. Your guide to treatment with Signifor LAR for acromegaly
PATIENT GUIDE Your guide to treatment with Signifor LAR for acromegaly Signifor LAR is indicated for the treatment of patients with acromegaly for whom surgery has not worked well enough or who cannot
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: somatostatin_analogs 7/2016 7/2017 7/2018 7/2017 Description of Procedure or Service Somatostatin, a hypothalamic
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationNIH Public Access Author Manuscript Pancreas. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Pancreas. 2008 July ; 37(1): 94 100. doi:10.1097/mpa.0b013e31816907ab. Clinical Value of Monitoring Plasma Octreotide Levels During
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationPathology testing and Neuroendocrine tumours (NETs)
Pathology testing and Neuroendocrine tumours (NETs) NETs are probably far more common than we think. Most grow so slowly and produce such widely varied and non-specific symptoms, or no symptoms at all,
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationClinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients
ORIGINAL ARTICLE Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients Eugene A. Woltering, MD, FACS,* Vergilio A. Salvo,
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 7 Last Review Date: November 30, 2018 Opioid Antagonist
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationFRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)
FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
differ and that they each has a unique mechanism of action. As such perc considered that it would be important for clinicians and patients to be able to choose either drug as a first-line treatment option.
More informationGLEEVEC PATIENT RESOURCES
GLEEVEC TALKING WITH YOUR DOCTOR ABOUT KIT+ GIST AND ITS TREATMENT When you have KIT-positive gastrointestinal stromal tumor (KIT+ GIST), you will likely have many questions and may, at times, feel overwhelmed
More informationSOMATULINE DEPOT (lanreotide) injection, for subcutaneous use Initial U.S. Approval: 2007
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOMATULINE safely and effectively. See full prescribing information for SOMATULINE. SOMATULINE (lanreotide)
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationWARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
More informationYou are being asked to take octreotide as a treatment to manage the symptoms of your cancer.
For the Patient: UGIOTLAR Symptomatic management of functional carcinoid and neuroendocrine tumours of the GI tract using Octreotide (SANDOSTATIN LAR) UGI = Undesignated, GastroIntestinal OT = Octreotide
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationPharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)
Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management
More informationSubject: Cobimetinib (Cotellic ) Tablet
09-J2000-53 Original Effective Date: 03/15/16 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Cobimetinib (Cotellic ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationOVERALL CLINICAL BENEFIT
noted that there are case reports of a rebound effect upon discontinuation of ruxolitinib (Tefferi 2012), although this was not observed in either the COMFORT I or COMFORT II studies. Therefore, perc considered
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationFactors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience
RESEARCH ARTICLE Editorial Process: Submission:00/00/0000 Acceptance:00/00/0000 : A 15-Year Single Center Experience Abdullah Sakin 1 *, Makbule Tambas 2, Saban Secmeler 3, Orçun Can 3, Serdar Arici 3,
More informationdaily; available as 10- mg g PO
Overview of the PRN: The Pain and Palliative Care PRN of ACCP is an organization of pharmacy practitioners, clinical scientists, pharmacy educators, and others. Its mission is to advance pain and palliative
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationPatient Experience Survey
Patient Experience Survey NET Patient Foundation Patient Experience Survey Objective: To understand the challenges faced by NET patients in reaching an appropriate diagnosis and then accessing the care
More informationQuality of Life and Survivorship:
Quality of Life and Survivorship: Implications for Future Ovarian Cancer Research and Care Lari Wenzel, PhD Professor of Medicine & Public Health Associate Director, Population Science and Cancer Control
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
Overall, perc considered that everolimus aligned with patient values. Patient advocacy group input on everolimus indicated that patients with pnets value the outcome of progression-free survival as a measure
More informationPalliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre
Palliative Care and the Critical Role of the Pharmacist Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre Overview What is palliative care Role of a pharmacist in palliative care Issues
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationPRUCAPLA Tablets (Prucalopride)
Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium
More informationIntestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response
Intestinal, non-intestinal, and extra-digestive response to linaclotide in patients with IBS-C: results at Week 4 predict sustained response Blanca Serrano, 1 Silvia Delgado-Aros, 2 Fermín Mearin, 3 Constanza
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More information